NeonMind Biosciences Inc. Logo

NeonMind Biosciences Inc.

NMDBF

(0.0)
Stock Price

0,01 USD

-1571.78% ROA

366.61% ROE

-0x PER

Market Cap.

11.659,75 USD

-60.41% DER

0% Yield

0% NPM

NeonMind Biosciences Inc. Stock Analysis

NeonMind Biosciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NeonMind Biosciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

NeonMind Biosciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NeonMind Biosciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

NeonMind Biosciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NeonMind Biosciences Inc. Revenue
Year Revenue Growth
2020 415.803
2021 0 0%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NeonMind Biosciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2020 269.520
2021 1.356.291 80.13%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NeonMind Biosciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2020 1.529.945
2021 4.632.731 66.98%
2022 759.620 -509.87%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NeonMind Biosciences Inc. EBITDA
Year EBITDA Growth
2020 -1.617.709
2021 -7.775.693 79.2%
2022 -969.620 -701.93%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NeonMind Biosciences Inc. Gross Profit
Year Gross Profit Growth
2020 415.553
2021 0 0%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NeonMind Biosciences Inc. Net Profit
Year Net Profit Growth
2020 -2.677.195
2021 -7.207.507 62.86%
2022 -714.456 -908.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NeonMind Biosciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2020 -3
2021 -7 71.43%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NeonMind Biosciences Inc. Free Cashflow
Year Free Cashflow Growth
2020 -853.447
2021 -5.824.338 85.35%
2022 19.258 30343.73%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NeonMind Biosciences Inc. Operating Cashflow
Year Operating Cashflow Growth
2020 -853.447
2021 -5.820.956 85.34%
2022 19.258 30326.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NeonMind Biosciences Inc. Capital Expenditure
Year Capital Expenditure Growth
2020 0
2021 3.382 100%
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NeonMind Biosciences Inc. Equity
Year Equity Growth
2019 -1.128.135
2020 -777.413 -45.11%
2021 290.295 367.8%
2022 -1.401.995 120.71%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NeonMind Biosciences Inc. Assets
Year Assets Growth
2019 140.089
2020 209.899 33.26%
2021 1.339.124 84.33%
2022 129.430 -934.63%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NeonMind Biosciences Inc. Liabilities
Year Liabilities Growth
2019 1.268.224
2020 987.312 -28.45%
2021 1.048.829 5.87%
2022 1.531.425 31.51%

NeonMind Biosciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-53.93
Price to Earning Ratio
-0x
Price To Sales Ratio
0x
POCF Ratio
-0
PFCF Ratio
-0.01
Price to Book Ratio
-0
EV to Sales
0
EV Over EBITDA
-0.47
EV to Operating CashFlow
-0.76
EV to FreeCashFlow
-0.76
Earnings Yield
-5196.46
FreeCashFlow Yield
-92.7
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
212.38
Graham NetNet
-37.59

Income Statement Metrics

Net Income per Share
-53.93
Income Quality
0.53
ROE
3.66
Return On Assets
-15.74
Return On Capital Employed
3.16
Net Income per EBT
1
EBT Per Ebit
1.16
Ebit per Revenue
0
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-28.65
Free CashFlow per Share
-28.65
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
3.59
Return on Tangible Assets
-15.72
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,85
Book Value per Share
-37,17
Tangible Book Value per Share
-37.17
Shareholders Equity per Share
-37.17
Interest Debt per Share
29.86
Debt to Equity
-0.6
Debt to Assets
6.54
Net Debt to EBITDA
-0.46
Current Ratio
0.19
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.6
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
72.64

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NeonMind Biosciences Inc. Dividends
Year Dividends Growth

NeonMind Biosciences Inc. Profile

About NeonMind Biosciences Inc.

NeonMind Biosciences Inc. engages in the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses. It is developing psilocybin-based products comprising mushroom-infused products and other mushroom-infused products to treat weight loss and management. The company was formerly known as Flourish Mushroom Labs Inc. and changed its name to NeonMind Biosciences Inc. in April 2020. NeonMind Biosciences Inc. was incorporated in 2019 and is based in Oakville, Canada. NeonMind Biosciences Inc. is a subsidiary of The Yield Growth Corp.

CEO
Ms. Penny Olga White B.A., BA,
Employee
0
Address
295 Robinson Street
Oakville, L6J 1G7

NeonMind Biosciences Inc. Executives & BODs

NeonMind Biosciences Inc. Executives & BODs
# Name Age
1 Mr. Jeff B. Smith B.A., M.B.A.
Co- Founder
70
2 Mr. Trevor Millar
Advisor
70
3 Mr. Ernie Ho
Vice President of Corporation Devel.
70
4 Mr. Yu Cai Huang CPA, CGA, M.B.A.
Chief Financial Officer
70
5 Ms. Tamara Melck
Chief Operating Officer
70
6 Mr. Robert D. Tessarolo
Chairman, Pres & Chief Executive Officer
70
7 Mr. Yu Cai Huang C.P.A., CGA, M.B.A.
Chief Financial Officer
70
8 Ms. Heather Williamson
Vice President of Corporation Fin., Corp. Sec. & Director
70

NeonMind Biosciences Inc. Competitors